Track Halozyme Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Halozyme Therapeutics, Inc. HALO Open Halozyme Therapeutics, Inc. in new tab

67.44 USD
P/E
23.55
EPS
2.85
P/B
36.22
ROE
99.40
Beta
0.88
Target Price
85.44 USD
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc.

🧾 Earnings Recap – Q1 2026

Halozyme’s shares rose 3.6% after reporting strong royalty revenue growth and reaffirming its 2026 guidance, with investors likely encouraged by the continued momentum in ENHANZE-enabled product adoption and a sizable new share buyback authorization.

  • Total revenue grew 42% year-over-year to $377 million, driven primarily by a 43% increase in royalties to $241 million from ENHANZE-enabled products.
  • Adjusted EBITDA reached $230 million, with non-GAAP EPS rising over 40% year-over-year to $1.60.
  • Full-year 2026 guidance and 2026-2028 financial outlook were reaffirmed, including a forecast of ENHANZE royalties exceeding $1 billion for the first time, up 30-35% over 2025.
  • Announced a new $1 billion share buyback authorization, targeting at least $400 million repurchased in 2026, supporting a projected 3% annual buyback yield in the coming years.
  • The company’s outlook emphasizes durable free cash flow, deleveraging plans, and selective capital deployment focused on drug delivery opportunities, though no expected M&A deals in 2026 beyond this area.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 4, 2026
P/E23.55
EPS2.85
Book Value1.85
Price to Book36.22
Debt/Equity991.21
% Insiders1.064%
Growth
Revenue Growth0.42%
Earnings Growth0.31%
Estimates
Forward P/E6.82
Forward EPS9.84
Target Mean Price85.44

DCF Valuation

Tweak assumptions to recompute fair value for Halozyme Therapeutics, Inc. (HALO)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Halozyme Therapeutics, Inc. Logo Halozyme Therapeutics, Inc. Analysis (HALO)

United States Health Care Official Website Stock

Is Halozyme Therapeutics, Inc. a good investment? Halozyme Therapeutics, Inc. (HALO) is currently trading at 67.44 USD. Market analysts have a consensus price target of 85.44 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 23.55. This valuation is generally in line with the broader market.

Earnings Schedule: Halozyme Therapeutics, Inc. is expected to release its next earnings report on Aug. 4, 2026. The market consensus estimate for Forward EPS is 9.84.

Investor FAQ

Does Halozyme Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Halozyme Therapeutics, Inc.?

Halozyme Therapeutics, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Aug. 4, 2026. The company currently has a trailing EPS of 2.85.

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Exchange Ticker
FRA (Germany) RV7.F
LSE (United Kingdom) 0J2O.L
NMS (United States) HALO

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion